However, the presence of PIK3CA mutations in BRAF mutated colorectal cancers leads to a numeric increase in the prevalence of MSI (from 59.5% to 68.2% in TCGA and from 47.1% to 62.9% in the DFCI cohort). This evidence concerns the gene BRAF and colorectal cancer.